Science to advance liver health
Nonalcoholic Fatty Liver Disease (NAFLD) is a worldwide problem affecting 25% to 35% of the total population. Patients with steatosis that also have other metabolic comorbidities have an increased risk of accelerated disease progression as well as a higher mortality. Early diagnosis and treatment are crucial to help slow or even reverse disease progression.
The forum provides you with the tools necessary to provide the best care for your patients.
Seeing the latest research, hearing clinical insights and having an opportunity to discuss with leading experts is an important way for you, the practitioner, to enhance your knowledge of NAFLD.